• Search History (Register)
  • MeSH Browser
Sort by Relevance
Search Results [14 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2025 Agency for Care Effectiveness (ACE) Mavacamten for treating obstructive hypertrophic cardiomyopathy
2025 NIHR Health Technology Assessment programme Bisoprolol for patients with chronic obstructive pulmonary disease at high risk of exacerbation: the BICS RCT
2024 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mavacamten (obstructive hypertrophic cardiomyopathy) – Addendum to Project A23-76]
2023 National Institute for Health and Care Excellence (NICE) Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy. NICE technology appraisal guidance 913
2023 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mavacamten (cardiomyopathy) – Benefit assessment according to §35a Social Code Book V]
2021 Institute for Clinical and Economic Review (ICER) Mavacamten for hypertrophic cardiomyopathy: effectiveness and value
2010 German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [New-onset diabetes and antihypertensive treatment]
2007 Blue Cross Blue Shield Association (BCBS) Special report: cardiovascular pharmacogenomics
2007 Canadian Agency for Drugs and Technologies in Health (CADTH) Ranolazine (Ranexa (TM)) for chronic stable angina
2005 Unit of Health Economics and Technology Assessment in Health Care (HunHTA) [Clinical effectiveness of carvedilol in comparison to -blockers, systematic review of the clinical and economic literature]
2003 German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) Effectiveness of glycoprotein IIb / IIIa receptor antagonists in the treatment of acute coronary syndroms (ACS)
2000 Centre for Clinical Effectiveness (CCE) Prophylactic beta-adrenergic blocking agents given perioperatively for preventing post-operative cardiac adverse events
2000 Centre for Clinical Effectiveness (CCE) Prophylactic beta-adrenergic blocking agents given perioperatively for preventing post-operative cardiac adverse events
1999 Agency for Healthcare Research and Quality (AHRQ) An evaluation of beta-blockers, calcium antagonists, nitrates, and alternative therapies for stable angina